Table 2 The ongoing clinical trials of Farnesyl-transferase inhibitors

NCT02535650

Urothelial carcinoma

Tipifarnib

Phase 2

NCT02210858

Chronic myeloid leukemia

Tipifarnib

Phase 1|Phase 2

NCT00847223

Mantle cell lymphoma

Tipifarnib

Phase 2

NCT00612651

Gliosarcoma

Temodar and SCH66336

Phase 1

NCT00354146

Leukemia, nonlymphocytic, acute

Tipifarnib (R115777)

Phase 2

NCT00112853

Leukemia

Tipifarnib|Etoposide

Phase 1

NCT00102635

Head and neck cancer

Fenretinide (4-HPR) | Drug: SCH66336

Phase 1

NCT00101153

Leukemia

Cytarabine|Daunorubicin hydrochloride|Tipifarnib

Phase 1

NCT00096122

Leukemia

Cytarabine|Idarubicin|Tipifarnib

Phase 1|Phase 2

NCT00093990

Leukemia

Tipifarnib;Zarnestra; R115777

Phase 3

NCT00093470

Leukemia

Tipifarnib

Phase 3

NCT00093418

Leukemia

Tipifarnib

Phase 2

NCT00004009

Leukemia

Tipifarnib

Phase 1

NCT00005041

Lung cancer

Tipifarnib

Phase 2

NCT00012350

Multiple myeloma

FTI

Phase 2

NCT00083096

Brain and central nervous system tumors

lonafarnib|Temozolomide

Phase 1

NCT00005989

Lung cancer

Tipifarnib

Phase 2

NCT00020774

Liver cancer

Gemcitabine hydrochloride|lonafarnib

Phase 2

NCT00006376

Bladder cancer|transitional cell cancer of the renal pelvis and ureter

Chemotherapy|Tipifarnib

Phase 2

NCT00006085

Unspecified adult solid tumor, protocol specific

CP-609,754

Phase 1

NCT00005848

Prostate cancer

Chemotherapy|Tipifarnib

Phase 2

NCT00005843

Pancreatic cancer

Tipifarnib

Phase 2

NCT00077519

Pancreatic cancer

Tipifarnib|Radiation

Phase 1

NCT00077363

Recurrent breast cancer|stage iv breast cancer

Tipifarnib|Capecitabine

Phase 2

NCT00076102

Neurofibromatosis 1|neurofibroma, plexiform

Pirfenidone

Phase 2

NCT00006213

Leukemia

BMS-214662

Phase 1

NCT00073450

Carcinoma, squamous cell|head and neck neoplasms

Farnesyl-protein transferase inhibitor

Phase 2

NCT00070252

Adult solid neoplasm| breast carcinoma

Capecitabine|Docetaxel|Tipifarnib

Phase 1|Phase 2

NCT00005845

Leukemia

Tipifarnib

Phase 1

NCT00003707

Unspecified adult solid tumor, protocol specific

Gemcitabine hydrochloride|Tipifarnib

Phase 1

NCT00022529

Unspecified adult solid tumor, protocol specific

BMS-214662|Trastuzumab|Pharmacological study

Phase 1

NCT00006242

Unspecified adult solid tumor, protocol specific

BMS-214662

Phase 1

NCT00055757

Stage IIIB non-small cell lung cancer|stage IV non-small cell lung cancer

Tipifarnib|Cisplatin|Gemcitabine hydrochloride

Phase 2

NCT00054470

Breast cancer

Trastuzumab|Tipifarnib

Phase 2

NCT00045396

Leukemia

Tipifarnib

Phase 2

NCT00027872

Leukemia

Tipifarnib

Phase 2

NCT00026104

Adenocarcinoma of the pancreas| pancreatic cancer

Gemcitabine hydrochloride|Paclitaxel|Tipifarnib|Radiation

Phase 2

NCT00025480

Lung cancer

Carboplatin|Paclitaxel|Tipifarnib|Radiation

Phase 1

NCT00025038

Juvenile myelomonocytic leukemia

Tipifarnib|Isotretinoin|Fludarabine phosphate|Cytarabine|Radiation|Cyclophosphamide|Anti-thymocyte globulin

Phase 2

NCT00006351

Bladder cancer|transitional cell cancer of the renal pelvis and ureter|urethral cancer

Gemcitabine hydrochloride|lonafarnib

Phase 2

NCT00005990

Unspecified adult solid tumor, protocol specific

Tipifarnib|Topotecan hydrochloride

Phase 1

NCT00005973

Unspecified adult solid tumor, protocol specific|unspecified childhood solid tumor, protocol specific

BMS-214662|Other: laboratory biomarker analysis

Phase 1

NCT00050986

Glioblastoma multiforme

Temozolomide|R115777

Phase 1|Phase 2

NCT00050336

Carcinoma, non-small-cell lung|metastases, neoplasm

Lonafarnib (SARASAR)

Phase 3

NCT00050141

Breast cancer

ZARNESTRA, Tipifarnib, R115777

Phase 2

NCT00048503

Acute myeloid leukemia

ZARNESTRA, Tipifarnib, R115777

Phase 2

NCT00040547

Neoplasms

Farnesyl-Protein Transferase Inhibitor

Phase 1

NCT00040534

Neoplasms

Farnesyl-Protein Transferase Inhibitor

Phase 1

NCT00038597

Myelogenous leukemia, chronic

SCH66336

Phase 2

NCT00038493

Glioblastoma multiforme

Temozolomide and SCH66336

Phase 2

NCT00034684

Leukemia

Farnesyl-protein transferase inhibitor

Phase 1|Phase 2

NCT00021541

Neurofibroma, plexiform|neurofibromatosis type I

Tipifarnib|Other: placebo

Phase 2